Clinical trial · Observational
Stereotactic Radiotherapy Management of Brain Metastases: the Value of a Longitudinal Multimodal Approach (POSTPONE)
Stereotactic Radiotherapy Management of Brain Metastases: the Value of a Longitudinal Multimodal Approach
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The management of brain metastases has evolved́ rapidly in recent years. It is estimated that 20% to 40% of cancer patients will develop brain metastases (BM) during the course of their disease. Whole-brain radiotherapy has long been the first-line treatment for brain metastases. However, large-scale international clinical trials conducted over the past decade have established stereotactic radiotherapy (SR) as the treatment of choice for the management of brain metastases (BM). However, even though the method of radiation delivery has evolved considerably, the problem of monitoring and managing brain metastases remains unresolved. This study therefore has several focuses: 1. Evaluation of the benefit of early remnographic assessment (6 weeks): impact on recurrence-free survival and overall survival. 2. Evaluation of a diagnostic approach to radionecrosis: complementarity of DOPA PET and multimodal MRI. 3. The benefits of longitudinal remnographic monitoring with the development of segmentation and automated follow-up tools
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases, Adult | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Risk factors of radionecrosis
- timeFrame
- Through study completion, an average of 1 year
- description
- The main objective is to identify risk factors for cerebral radionecrosis after stereotactic radiotherapy in patients treated for brain metastases.
Secondary outcomes (2)
- measure
- Risk factors of local relapse
- timeFrame
- Through study completion, an average of 1 year
- description
- Clinical, dosimetric and radiological factors influencing local control
- measure
- Post-SRT follow-up
- timeFrame
- Through study completion, an average of 1 year
- description
- Practical analysis of the benefits of performing MRI 6 weeks after the end of stereotactic radiotherapy treatment, and determining precise criteria to better target patients who would benefit most from it.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Patients with solid cancer with brain metastases treated by hypofractionated external stereotactic radiotherapy at the CHRU de Brest between 01/01/2014 and 31/12/2022 * Patient affiliated to a social security scheme Exclusion Criteria: * Patients with primary brain tumors * Patients treated with normofractionated external cerebral radiotherapy * Age \< 18 years * Patients under legal protection (guardianship, curatorship, etc.)
References
Publications (0)
Data not yet available